BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived biologics for advanced wound care, has scheduled its Third Quarter 2024 financial results release for Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 PM ET, featuring CEO Jason Matuszewski and CFO Michael Fortunato discussing quarterly results. The event will be accessible via phone and webcast, with both domestic and international dial-in options available.
BioStem Technologies (OTC: BSEM), un'azienda MedTech specializzata in biologici derivati dalla placenta per la cura delle ferite avanzate, ha programmato la pubblicazione dei suoi risultati finanziari del terzo trimestre 2024 per martedì 12 novembre 2024. L'azienda organizzerà una conferenza telefonica e un webcast alle 16:30 ET, con il CEO Jason Matuszewski e il CFO Michael Fortunato che discuteranno i risultati trimestrali. L'evento sarà accessibile tramite telefono e webcast, con opzioni di accesso sia nazionali che internazionali disponibili.
BioStem Technologies (OTC: BSEM), una empresa de tecnología médica especializada en biológicos derivados de la placenta para el cuidado avanzado de heridas, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre de 2024. La empresa llevará a cabo una llamada de conferencia y un webcast a las 4:30 PM ET, con el CEO Jason Matuszewski y el CFO Michael Fortunato discutiendo los resultados trimestrales. El evento será accesible por teléfono y webcast, con opciones de llamada disponibles tanto nacionales como internacionales.
BioStem Technologies (OTC: BSEM), 고급 상처 치료를 위한 태반 유래 생물학에 특화된 메드텍 회사가 2024년 3분기 재무 실적 발표를 2024년 11월 12일 화요일로 예정했습니다. 회사는 CEO Jason Matuszewski와 CFO Michael Fortunato가 분기 결과를 논의하는 4:30 PM ET에 전화 회의와 웹캐스트를 개최할 예정입니다. 이 행사는 전화와 웹캐스트를 통해 접근 가능하며, 국내외 통화 옵션이 모두 제공됩니다.
BioStem Technologies (OTC: BSEM), une entreprise de MedTech spécialisée dans les biologiques dérivés du placenta pour les soins avancés des plaies, a prévu la publication de ses résultats financiers du troisième trimestre 2024 pour le mardi 12 novembre 2024. L'entreprise animera une conférence téléphonique et un webcast à 16h30 ET, avec le PDG Jason Matuszewski et le directeur financier Michael Fortunato discutant des résultats trimestriels. L'événement sera accessible par téléphone et par webcast, avec des options de connexion nationales et internationales disponibles.
BioStem Technologies (OTC: BSEM), ein MedTech-Unternehmen, das sich auf aus der Plazenta gewonnene Biologika für die fortgeschrittene Wundversorgung spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 für Dienstag, den 12. November 2024, geplant. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, in dem CEO Jason Matuszewski und CFO Michael Fortunato die Quartalsergebnisse besprechen. Die Veranstaltung wird sowohl telefonisch als auch über ein Webcast zugänglich sein, mit verfügbaren nationalen und internationalen Einwahloptionen.
- None.
- None.
Conference Call and Webcast to be held at 4:30 PM ET
POMPANO BEACH, Fla., Oct. 28, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its Third quarter 2024 financial results on Tuesday, November 12, 2024, and host a conference call and webcast at 4:30 PM ET to discuss the results.
The webcast will feature an overview of the quarter from Jason Matuszewski, CEO, and Michael Fortunato, CFO. To register for the event, please click HERE.
Conference Call & Webcast Information:
- Conference ID: 9695874
- USA / International Toll: +1 (646) 307-1963
- USA - Toll-Free: (800) 715-9871
- Canada – Toronto: (647) 932-3411
- Canada - Toll-Free: (800) 715-9871
- Webcast Link: https://events.q4inc.com/attendee/565640065
The live and archived webcast of the call will also be available on the BioStem Technologies website under the Investors section or by clicking HERE.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and Linkedin.
Join BioStem's Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on Twitter and LinkedIn.
Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate", "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
646-863-6893
FAQ
When will BioStem Technologies (BSEM) release Q3 2024 earnings?
What time is BioStem Technologies (BSEM) Q3 2024 earnings call?
Who will present at BioStem Technologies (BSEM) Q3 2024 earnings call?
